Showing results (171-180 of 226) with videos related to

Sort By:
Pageof 23
Lancet (London, England)|April 4, 2023
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trialHiddo J L Heerspink, Jai Radhakrishnan, Charles E Alpers, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 4, 2026
Design and baseline characteristics of the ZENITH high proteinuria trial testing zibotentan/dapagliflozin efficacy in CKDHiddo J L Heerspink, Clare Arnott, Jonathan Barratt, et al.
Lancet (London, England)|April 2, 2017
Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trialBengt C Fellström, Jonathan Barratt, Heather Cook, et al.
Kidney International Reports|May 14, 2023
IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT StudyJonathan Barratt, Brad Rovin, Muh Geot Wong, et al.
Kidney International|June 6, 2024
The role of complement in kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies ConferenceMarina Vivarelli, Jonathan Barratt, Laurence H Beck, et al.
Nature Communications|January 28, 2023
Next-Generation Morphometry for pathomics-data mining in histopathologyDavid L Hölscher, Nassim Bouteldja, Mehdi Joodaki, et al.
Kidney International Reports|May 20, 2024
Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX StudyHoward Trachtman, Jai Radhakrishnan, Michelle N Rheault, et al.
Clinical Journal of the American Society of Nephrology : CJASN|January 13, 2019
Proteinuria Reduction as a Surrogate End Point in Trials of IgA NephropathyAliza Thompson, Kevin Carroll, Lesley A Inker, et al.
Clinical Journal of the American Society of Nephrology : CJASN|June 11, 2026
Humoral Response to COVID-19 Vaccines and Infection During Sibeprenlimab Treatment of IgA Nephropathy: Data from the ENVISION TrialKieran McCafferty, Jonathan Barratt, Yusuke Suzuki, et al.
Autoimmunity Reviews|September 17, 2020
Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown?Philipp Gauckler, Jae Il Shin, Federico Alberici, et al.
Pageof 23